Q2 2017 and investor event
We announced our second quarter 2017 results on 26 July and hosted an investor event where Emma Walmsley, CEO, and Simon Dingemans, CFO, spoke about our strategic priorities and financial outlook.
- Q2 2017 results announcement PDF - 1.9MB
- Q2 2017 results video transcript PDF - 177.6KB
- Q2 2017 US dollar translation PDF - 121.7KB
- Q2 2017 results infographic PDF - 862.6KB
- Q2 2017 pre announcement aide memoire PDF - 795.1KB
- Emma Walmsley slides: Key priorities PDF - 864.3KB
- Simon Dingemans slides: Q2 and financial outlook PDF - 509.3KB
- Investor event full transcript PDF - 173.6KB
2010 Fourth Quarter - released 03 February 2011
Andrew Witty, CEO, discusses our fourth quarter results 2010.
2010 Third Quarter - released 21 October 2010
Andrew Witty, CEO, discusses our third quarter results 2010
- Q3 EPS before major restructuring of 28.2p
- Q3 dividend up 7% to 16p
2010 Second Quarter - released 21 July 2010
Andrew Witty, CEO, discusses our second quarter results 2010.
- Q2 EPS before major restructuring 2.6p (29.3p excluding pre-announced legal charge)
- Q2 dividend increased 7% to 15p
2010 First Quarter - released 28 April 2010
Andrew Witty, CEO, discusses our first quarter results 2010.
- Q1 sales £7.4bn up 13% CER
- Underlying sales (excluding pandemic products) up 4% CER
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III